J. Pérez-Castells et al.
H), 7.14 (d, J = 8.8 Hz, 2 H), 7.65 (s, 1 H) ppm. 13C NMR son–Khand intermolecular reactions afforded pure 11a (0.17 g,
FULL PAPER
(75 MHz, CDCl3): δ = 13.0, 13.7, 16.2, 19.1, 22.6, 36.8, 55.1, 114.7,
119.5, 121.0, 129.7, 132.4, 140.3, 159.5, 169.9, 170.2, 204.3 ppm.
71%) as a yellow oil after flash chromatography (hexane/AcOEt,
4:1). H NMR (300 MHz, CDCl3): δ = 0.98 (t, J = 7.2 Hz, 3 H),
1
n.O.e (H7.65 Ǟ H2.60, 8.2%; Ǟ H1.22, 4.5%). IR (film): ν = 1670,
1.19–1.24 (m, 6 H), 2.03 (d, J = 1.1 Hz, 2 H), 2.21 (q, J = 7.7 Hz,
˜
1640 cm–1. C19H23NO3 (313.39): calcd. C 72.82, H 7.40, N 4.47; 2 H), 2.57 (q, J = 7.7 Hz, 2 H), 3.84 (s, 3 H), 4.23 (q, J = 7.1 Hz,
found C 72.54, H 7.67, N 4.40.
2 H), 6.88 (d, J = 6.6 Hz, 2 H), 7.10 (d, J = 6.6 Hz, 2 H), 7.34 (s,
1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 13.3, 14.0, 14.3, 16.5,
19.5, 37.3, 55.3, 62.9, 114.3, 119.5, 122.8, 129.5, 131.6, 140.3, 154.7,
N-[(E)-(2,3-Diethyl-4-oxocyclopent-2-en-1-ylidene)methyl]-N-(4-
fluorophenyl)acetamide (8a): Treatment of hex-3-yne (0.16 g,
1.96 mmol) and N-(4-fluorophenyl)-N-(propa-1,2-dienyl)acetamide
(0.25 g, 1.31 mmol) as described in Procedure A for Pauson–Khand
intermolecular reactions afforded pure 8a (0.27 g, 61%) as a yellow
oil after flash chromatography (hexane/AcOEt, 4:1). 1H NMR
(300 MHz, CDCl3): δ = 0.95 (t, J = 7.7 Hz, 3 H), 1.19 (t, J =
7.7 Hz, 3 H), 1.92 (s, 3 H), 1.96 (s, 2 H), 2.19 (q, J = 7.5 Hz, 2 H),
2.57 (q, J = 7.7 Hz, 2 H), 7.15–7.22 (m, 4 H), 7.60 (s, 1 H) ppm.
13C NMR (75 MHz, CDCl3): δ = 13.2, 13.9, 16.5, 19.4, 22.9, 37.1,
117.1 (d, J = 22.5 Hz), 120.5, 121.1, 130.7 (d, J = 8.4 Hz), 136.3
(d, J = 3.1 Hz), 141.1, 162.4 (d, J = 249.5 Hz), 169.1, 170.0,
204.2 ppm. n.O.e (H7.60 Ǟ H2.57, 7.8%; Ǟ H1.19, 3.6%). IR (film):
159.1, 169.8, 204.8 ppm. n.O.e (H7.34 Ǟ H2.57, 4.8 %; Ǟ H1.22
,
2.6%). IR (film): ν = 1710, 1680, 1650 cm–1. C H NO (343.42):
˜
20 25
4
calcd. C 69.95, H 7.34, N 4.08; found C 70.24, H 7.55, N 3.86.
N-(4-Methoxyphenyl)-4-methyl-N-{(E)-[3-(4-methylphenyl)-4-oxo-
cyclopent-2-en-1-ylidene]methyl}benzenesulfonamide (12a): Treat-
ment of 1-ethynyl-4-methylbenzene (80 mg, 0.71 mmol) and N-(4-
methoxyphenyl)-4-methyl-N-(propa-1,2-dienyl)benzenesulfon-
amide (150 mg, 0.48 mmol) as described in Procedure A for Pau-
son–Khand intermolecular reactions afforded pure 12a (80 mg,
35%) as a brown oil after flash chromatography (hexane/AcOEt,
4:1). After treatment as described in Procedure C, the reaction af-
forded 12a (0.20 g, 55%) from allenamide 3d (0.25 g, 0.79 mmol).
1H NMR (300 MHz, CDCl3): δ = 2.18 (s, 2 H), 2.35 (s, 3 H), 2.46
(s, 3 H), 3.85 (s, 3 H), 6.84 (d, J = 9.4 Hz, 2 H), 6.93 (d, J = 8.8 Hz,
2 H), 7.17 (d, J = 7.7 Hz, 2 H), 7.31 (d, J = 8.2 Hz, 2 H), 7.34 (s,
1 H), 7.58 (d, J = 8.2 Hz, 2 H), 7.62 (d, J = 8.2 Hz, 2 H), 7.93 (s,
1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 21.3, 21.7, 38.9, 55.4,
114.6, 118.2, 126.4, 126.6, 127.7, 128.6, 129.2, 129.5, 129.8, 131.6,
ν = 1675, 1640 cm–1. C H FNO (301.36): calcd. C 71.74, H 6.69,
˜
18 20
2
N 4.65; found C 71.40, H 6.39, N 4.70.
N-[(E)-(2,3-Diethyl-4-oxocyclopent-2-en-1-ylidene)methyl]-N-(2-eth-
enylphenyl)acetamide (9a): Treatment of hex-3-yne (0.10 g,
1.19 mmol) and N-(propa-1,2-dienyl)-N-(2-vinylphenyl)acetamide
(0.15 g, 0.75 mmol) as described in Procedure A for Pauson–Khand
intermolecular reactions afforded pure 9a (0.13 g, 58%) as a yellow
oil after flash chromatography (hexane/AcOEt, 4:1). After treat-
ment as described in Procedure C, the reaction afforded 9a (0.33 g,
85%) from allenamide 3c (0.25 g, 1.26 mmol). 1H NMR (300 MHz,
CDCl3): δ = 0.93 (t, J = 7.4 Hz, 3 H), 1.19 (t, J = 7.7 Hz, 3 H),
1.82 (d, J = 20.9 Hz, 1 H), 1.83 (s, 3 H), 1.93 (d, J = 20.9 Hz, 1
H), 2.16 (q, J = 7.5 Hz, 2 H), 2.57 (q, J = 7.5 Hz, 2 H), 5.36 (d, J
= 11.0 Hz, 1 H), 5.80 (d, J = 17.6 Hz, 1 H), 6.58 (dd, J1 = 17.6, J2
= 11.0 Hz, 1 H), 7.15 (d, J = 7.1 Hz, 1 H), 7.34 (t, J = 7.1 Hz, 1
H), 7.43 (t, J = 7.4 Hz, 1 H), 7.65 (d, J = 8.2 Hz, 1 H), 7.69 (s, 1
H) ppm. 13C NMR (75 MHz, CDCl3): δ = 13.2, 14.0, 16.4, 19.6,
22.6, 36.5, 118.2, 119.5, 120.4, 126.5, 129.2, 129.5, 129.8, 130.6,
136.3, 137.4, 140.8, 170.1, 204.7 ppm. n.O.e (H7.69 Ǟ H2.57, 4.3%;
134.6, 137.5, 138.1, 144.7, 155.2, 160.3, 203.2 ppm. n.O.e (H7.93
Ǟ
.
H7.34, 18.0 %). IR (film): ν = 1680, 1620, 1350, 1160 cm–1
˜
C27H25NO4S (459.56): calcd. C 70.57, H 5.48, N 3.05; found C
70.33, H 5.65, N 3.30.
(E)-N-(4-Methoxyphenyl)-4-methyl-N-[4-oxo-2-propyl-3-(trimethyl-
silanyl)cyclopent-2-enylidenemethyl]benzenesulfonamide (13a) and
(E)-N-(4-Methoxyphenyl)-4-methyl-N-[4-oxo-3-propyl-2-(trimethyl-
silanyl)cyclopent-2-enylidenemethyl]benzenesulfonamide (13c):
Treatment of trimethyl(pent-1-ynyl)silane (0.22 mL, 1.19 mmol)
and N-(4-methoxyphenyl)-4-methyl-N-(propa-1,2-dienyl)benzene-
sulfonamide (0.25 g, 0.79 mmol) as described in Procedure A for
Pauson–Khand intermolecular reactions afforded 13a and 13c
(0.33 g, 85%) as a mixture of isomers (4:1). After purification by
flash chromatography (hexane/AcOEt, 6:1), pure 13a (0.28 g, 73%)
was obtained as a brown oil.
Ǟ H1.19, 2.5 %). IR (film): ν = 1680, 1640 cm–1. C20H23NO2
˜
(309.40): calcd. C 77.64, H 7.49, N 4.53; found C 77.38, H 7.58, N
4.32.
1
Data for 13a: H NMR (300 MHz, CDCl3): δ = 0.18 (s, 9 H), 1.08
N-[(E)-(2,3-Diethyl-4-oxocyclopent-2-en-1-ylidene)methyl]-N-(4-
methoxyphenyl)-4-methylbenzenesulfonamide (10a): Treatment of
hex-3-yne (0.10 g, 1.19 mmol) and N-(4-methoxyphenyl)-4-methyl-
N-(propa-1,2-dienyl)benzenesulfonamide (0.25 g, 0.79 mmol) as de-
scribed in Procedure A for Pauson–Khand intermolecular reac-
tions afforded pure 10a (0.29 g, 85%) as a white solid after flash
(t, J = 7.4 Hz, 3 H), 1.54–1.67 (m, 2 H), 1.96 (br. s, 2 H), 2.44 (s,
3 H), 2.59–2.64 (m, 2 H), 3.81 (s, 3 H), 6.78–6.82 (m, 2 H), 6.85–
6.90 (m, 2 H), 7.29 (d, J = 8.2 Hz, 2 H), 7.30 (s, 1 H), 7.54 (d, J =
8.2 Hz, 2 H) ppm. 13C NMR (75 MHz, CDCl3): δ = –0.4, 14.5,
21.6, 24.3, 30.5, 38.4, 55.4, 114.4, 121.3, 123.3, 127.6, 128.9, 129.7,
1
131.4, 134.7, 138.1, 144.5, 160.0, 181.0, 209.0 ppm. n.O.e (H2.59 Ǟ
chromatography (hexane/AcOEt, 2:1 to 1:1). M.p. 122–124 °C. H
H
7.30, 12.0%; Ǟ H0.18, 5.4%). IR (film): ν = 1670, 1630, 1360,
˜
NMR (300 MHz, CDCl3): δ = 0.91 (t, J = 7.7 Hz, 3 H), 1.18 (t, J
= 7.7 Hz, 3 H), 1.96 (s, 2 H), 2.14 (q, J = 7.7 Hz, 2 H), 2.38 (s, 3
H), 2.53 (q, J = 7.7 Hz, 2 H), 3.75 (s, 3 H), 6.75 (d, J = 9.3 Hz, 2
H), 6.85 (d, J = 8.8 Hz, 2 H), 7.16 (s, 1 H), 7.24 (d, J = 8.2 Hz, 2
H), 7.50 (d, J = 8.2 Hz, 2 H) ppm. 13C NMR (75 MHz, CDCl3): δ
= 13.2, 13.8, 16.3, 19.3, 21.4, 37.0, 55.2, 114.3, 119.1, 122.0, 127.4,
129.2, 129.6, 131.2, 134.6, 140.4, 144.3, 159.8, 169.0, 204.2 ppm.
1170 cm–1. C26H33NO4SSi (483.70): calcd. C 64.56, H 6.88, N 2.90,
S 6.63; found C 67.31, H 6.65, N 3.08, S 6.49.
Data for 13c: Mixture of isomers 13c and 13a. 1H NMR (300 MHz,
CDCl3): δ = 0.44 (s, 9 H), 0.90 (t, J = 7.4 Hz, 3 H), 1.26–1.36 (m,
2 H), 2.06 (s, 2 H), 2.22–2.27 (m, 2 H), 2.45 (s, 3 H), 3.83 (s, 3 H),
6.79–6.82 (m, 2 H), 6.86–6.94 (m, 2 H), 7.23 (br. s, 1 H), 7.27–7.31
(m, 2 H), 7.50–7.56 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3): δ
= 0.9, 14.1, 23.4, 27.1, 29.6, 37.5, 55.3, 114.3, 124.9, 125.8, 129.5,
129.6, 130.0, 131.0, 134.6, 152.0, 154.4, 159.7, 166.8, 205.7 ppm.
n.O.e (H7.16 Ǟ H2.53, 5.8%; Ǟ H1.18, 3.0%). IR (KBr): ν = 1690,
˜
1630, 1350, 1180 cm–1. C24H27NO4S (425.54): calcd. C 67.74, H
6.40, N 3.29, S 7.54; found C 67.87, H 6.48, N 3.41, S 7.26.
Ethyl [(E)-(2,3-Diethyl-4-oxocyclopent-2-en-1-ylidene)methyl](4-
methoxyphenyl)carbamate (11a): Treatment of hex-3-yne (0.10 g,
1.19 mmol) and ethyl N-(4-methoxyphenyl)(propa-1,2-dienyl)car-
bamate (0.15 g, 0.75 mmol) as described in Procedure A for Pau-
(E)-N-[2-(tert-Butyldimethylsilanyl)oxymethyl-4-oxo-3-(trimethylsil-
anyl)cyclopent-2-enylidenemethyl]-N-(4-methoxyphenyl)-4-methyl-
benzenesulfonamide (14a), (Z)-N-[3-(tert-Butyldimethylsilanyl)oxy-
methyl-4-oxo-2-(trimethylsilanyl)cyclopent-2-enylidenemethyl]-N-(4-
1374
www.eurjoc.org
© 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Eur. J. Org. Chem. 2008, 1370–1377